ANI Pharmaceuticals (ANIP) closed the last trading session at $56.79, gaining 2.4% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $81.20 indicates a 43% upside potential.The mean estimate comprises five short-term price targets with a standard deviation of $13.70. While the lowest estimate of $60 indicates a 5.7% increase from the current price level, the most optimistic analyst e ...

Core Insights - The Zacks Rank system emphasizes earnings estimates and revisions to identify winning stocks, with a focus on value investing as a popular strategy in various market conditions [1] - Zacks has introduced the Style Scores system to highlight stocks with specific characteristics, particularly those with high grades in the "Value" category, which are considered strong value stocks when combined with a high Zacks Rank [1] Company Summary: ANI Pharmaceuticals (ANIP) - ANI Pharmaceuticals currently holds a Zacks Rank of 2 (Buy) and has received a Value grade of A, indicating strong potential for value investors [2] - The company's price-to-book (P/B) ratio is 2.64, which is favorable compared to the industry average of 3.88. Over the past 12 months, ANIP's P/B ratio has fluctuated between 2.31 and 3.30, with a median of 2.83 [2] - ANI Pharmaceuticals has a price-to-cash flow (P/CF) ratio of 12.75, which is attractive relative to the industry average of 15.70. The P/CF ratio has ranged from 11.93 to 19.50 over the past 52 weeks, with a median of 13.70 [2] - These metrics suggest that ANI Pharmaceuticals is likely undervalued at present, especially when considering its strong earnings outlook, making it an impressive value stock [3]

PRINCETON, N.J., Sept. 26, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that following final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), the Company launched Ketoconazole Shampoo, 2%. ANI’s Ketoconazole Shampoo, 2% is the generic version of the reference listed drug (RLD) Nizoral®. "We are proud to announce the FDA approval and commercialization of Ketoconazole Shampoo, 2%, another limite ...

PRINCETON, N.J., Sept. 13, 2024 (GLOBE NEWSWIRE) --  ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Promethazine Hydrochloride and Dextromethorphan Hydrobromide Oral Solution, 6.25 mg/15 mg per 5 mL. "The launch of Promethazine Hydrochloride and Dextromethorphan Hydrobromide Oral Solution just prior to the onset of cough and cold season is especially timely. With our 14th new product launch this year, we continue to drive strong growth in our Generics business,” ...

PRINCETON, N.J. and ATLANTA, Sept. 11, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) (“ANI”) and Alimera Sciences, Inc. (NASDAQ: ALIM) (“Alimera” or the “Company”) today jointly announced that they have scheduled the closing of their transaction pursuant to the companies’ previously announced Merger Agreement for before the market opens on Monday, September 16, 2024. About ANI Pharmaceuticals, Inc.ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified biopharmaceutical company serving ...

Here at Zacks, we focus on our proven ranking system, which places an emphasis on earnings estimates and estimate revisions, to find winning stocks. But we also understand that investors develop their own strategies, so we are constantly looking at the latest trends in value, growth, and momentum to find strong companies for our readers.Looking at the history of these trends, perhaps none is more beloved than value investing. This strategy simply looks to identify companies that are being undervalued by the ...

PRINCETON, N.J., Aug. 13, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the closing of its offering of $316,250,000 aggregate principal amount of 2.25% convertible senior notes due 2029 (the “notes”) in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). In response to investor demand, ANI upsized the initial offering of $250,000,000 aggregate principal amount ...

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Q2 2024 Earnings Conference Call August 6, 2024 8:30 AM ET Company Participants Lisa Wilson - IR Nikhil Lalwani - President, CEO & Director Christopher Mutz - SVP, Head, Rare Diseases Stephen Carey - CFO & SVP Conference Call Participants Les Sulewski - Truist Securities Gary Nachman - Raymond James & Associates Vamil Divan - Guggenheim Securities Oren Livnat - H.C. Wainwright & Co. Tim Chiang - Capital One Operator Good day, everyone, and welcome to today's ANI Pharm ...

Core Viewpoint - ANI Pharmaceuticals, Inc. has announced the pricing of a $275 million offering of 2.25% convertible senior notes due 2029, increasing from a previously announced size of $250 million, with settlement scheduled for August 13, 2024 [1][4]. Summary by Sections Offering Details - The offering consists of senior, unsecured obligations with a 2.25% annual interest rate, payable semi-annually starting March 1, 2025, and maturing on September 1, 2029 [2]. - Noteholders can convert their notes under specific conditions before June 1, 2029, and at any time thereafter until two trading days before maturity, with an initial conversion rate of 13.4929 shares per $1,000 principal amount, equating to a conversion price of approximately $74.11 per share, representing a 30% premium over the last reported price of $57.01 on August 7, 2024 [2][3]. Redemption and Repurchase Rights - The notes are redeemable at ANI's option starting September 1, 2027, under certain conditions, including if the stock price exceeds 130% of the conversion price [3]. - In the event of a "fundamental change," noteholders may require ANI to repurchase their notes for cash at the principal amount plus accrued interest [3]. Use of Proceeds - ANI estimates net proceeds from the offering to be approximately $266.8 million, or $306.8 million if the option for additional notes is fully exercised. Approximately $35.3 million will fund capped call transactions, while the remainder will repay existing senior secured term loans [4]. - The company plans to enter a new senior secured credit agreement for a $325 million delayed draw term loan and a $75 million revolving facility, expected to be effective concurrently with the offering's closing [4]. Capped Call Transactions - ANI has entered into capped call transactions to reduce potential dilution from the conversion of notes, which will cover shares of common stock underlying the notes [5]. - If the market price exceeds the cap price of these transactions, dilution may still occur [6]. Company Overview - ANI Pharmaceuticals is a diversified biopharmaceutical company focused on developing, manufacturing, and marketing high-quality branded and generic prescription products, particularly for high unmet medical needs [9].

PRINCETON, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the pricing of its offering of $275,000,000 aggregate principal amount of 2.25% convertible senior notes due 2029 (the “notes”) in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The offering size was increased from the previously announced offering size of $250,000,000 aggregate princi ...